相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Veerisa Vimolchalao et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hironobu Hashimoto et al.
LANCET ONCOLOGY (2020)
Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis
Ronald Chow et al.
SUPPORTIVE CARE IN CANCER (2020)
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy
Suthinee Ithimakin et al.
SUPPORTIVE CARE IN CANCER (2020)
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients
Winnie Yeo et al.
BREAST (2020)
Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting A Randomized Pilot Trial
Rudolph M. Navari et al.
JAMA ONCOLOGY (2020)
Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials
Jian-Guo Zhou et al.
ESMO OPEN (2020)
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study
So-Yeon Jeon et al.
CANCER RESEARCH AND TREATMENT (2019)
Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study
Luigi Celio et al.
TUMORI JOURNAL (2019)
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide
Piyawan Tienchaiananda et al.
ANNALS OF PALLIATIVE MEDICINE (2019)
1766PEfficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy
S C Saldanha et al.
ANNALS OF ONCOLOGY (2019)
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal
Soniya Dulal et al.
JOURNAL OF GLOBAL ONCOLOGY (2019)
Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study
J. Flank et al.
SUPPORTIVE CARE IN CANCER (2018)
Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis
Karin Jordan et al.
SUPPORTIVE CARE IN CANCER (2018)
The latest consensus on antiemetics
Jorn Herrstedt
CURRENT OPINION IN ONCOLOGY (2018)
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis
Ronald Chow et al.
SUPPORTIVE CARE IN CANCER (2018)
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan
Alaa A. M. Osman et al.
JOURNAL OF GLOBAL ONCOLOGY (2018)
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults
Anna Sutherland et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials
Ronald Chow et al.
ANNALS OF PALLIATIVE MEDICINE (2018)
Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study
Sandip Mukhopadhyay et al.
SUPPORTIVE CARE IN CANCER (2017)
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation
Midori Nakagaki et al.
SUPPORTIVE CARE IN CANCER (2017)
2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents
Karin Jordan et al.
SUPPORTIVE CARE IN CANCER (2017)
The use of olanzapine compared to aprepitant as antiemetic for prevention of chemotherapy induced nausea and vomiting in highly emetogenic chemotherapy - a randomized trial
S. Sapkota et al.
EUROPEAN JOURNAL OF CANCER (2017)
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Paul J. Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
NCCN Guidelines® Insights Antiemesis, Version 2.2017 Featured Updates to the NCCN Guidelines
Michael J. Berger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
Beverley J. Shea et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
Beverley J. Shea et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Olanzapine versus aprepitant in the prevention of chemotherapy induced nausea and vomiting (CINV) in breast cancer patients.
S. Mukesh et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis
Jukapun Yoodee et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial
Masakazu Abe et al.
SUPPORTIVE CARE IN CANCER (2016)
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review
Ronald Chow et al.
SUPPORTIVE CARE IN CANCER (2016)
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
F. Roila et al.
ANNALS OF ONCOLOGY (2016)
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis
Leonard Chiu et al.
SUPPORTIVE CARE IN CANCER (2016)
Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting
Rudolph M. Navari et al.
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY (2016)
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer
Xin Wang et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index
Michael Walsh et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2014)
Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study
Alexander Molassiotis et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2014)
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study
Naomi Mizukami et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2014)
Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review
Christopher M. Hocking et al.
SUPPORTIVE CARE IN CANCER (2014)
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Rudolph M. Navari et al.
SUPPORTIVE CARE IN CANCER (2013)
Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial
Rudolph M. Navari et al.
SUPPORTIVE CARE IN CANCER (2010)
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Lijun Tan et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study
Rudolph M. Navari et al.
SUPPORTIVE CARE IN CANCER (2007)
Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings
Lorenzo Cohen et al.
SUPPORTIVE CARE IN CANCER (2007)
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study
RM Navari et al.
SUPPORTIVE CARE IN CANCER (2005)
A phase I trial of olanzapine (zyprexa) for the prevention of delayed emesis in cancer patients: A Hoosier Oncology Group Study
SD Passik et al.
CANCER INVESTIGATION (2004)
A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain
SD Passik et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2002)
分享论文
